Exhibit 99.1
Certain statements contained herein constitute "forward looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Such
forward looking statements are identified by words such as "intends,"
"anticipates," "believes," "expects" and "hopes" and include, without
limitation, statements regarding the Company's plan of business operations,
future financings and completion of certain transactions. Factors that could
cause actual results to differ materially include, among others, the following:
acceptability of the Company's services in the market place, succesful receipt
of financing, general economic conditions, competition and decisions of third
parties over which the Company has no control. Most of these factors are outside
the control of the Company. Investors are cautioned not to put undue reliance on
forward looking statements. Except as otherwise required by applicable
securities statutes or regulations, the Company disclaims any intent or
obligation to update publicly these forward looking statements, whether as a
result of new information, future events or otherwise.
Slide 1:
--------
[[Graphic image of Vitro Diagnostics, Inc. logo and
"Naturally Pure Therapeutics(TM)" 1999]]
ANNUAL MEETING OF SHAREHOLDERS
December 1, 2000
Presented by Dr. Jim Musick President and CEO
Slide 2:
--------
Agenda:
Who we are
What we've accomplished
Plans for the future
Slide 3:
--------
Who We Are
Vitro's mission:
We create proprietary therapeutic products which provide breakthrough
medical benefits to patients and/or significant cost savings to the
healthcare system
Slide 4:
--------
Who We Are
Vitro's vision:
To become a major producer of products to treat human infertility, and
the world leader in the creation of new medical products from cell
immortalization
3
<PAGE>
Slide 5:
--------
Who We Are
Vitro's Values:
We value people
We value innovation
We value persistence
We value excellence
Slide 6:
--------
Who We Are
Vitro values people and will always treat them as we want to be treated
ourselves, because:
People (all of us) are people
People (our shareholders)allow us the opportunity to produce
People (our employees) produce products
People (our patients) need and benefit from our products
People (our customers) pay for our products
Slide 7:
--------
What We've Accomplished
Restructuring in summer 2000
New executive management team
Spun-off antigen business
Erased all debt
Significantly increased available cash
Attracted exceptional outside Board members
Slide 8:
--------
What We've Accomplished
Established fertility product pipeline
VITROPINtm
VITROPIN-Ctm
VITROJECTtm
VITROCELLtm
Slide 9:
--------
What We've Accomplished
Breakthrough cell immortalization technology
Natural therapeutics:
VITROCELL (tm)
Other cell line products
Cells for:
Drug discovery
Cell transplantation
Artificial organs
4
<PAGE>
Slide 10:
---------
What We've Accomplished
Milestone achievements:
First patent issued
Three patents filed
NIH grant awarded
Submission to FDA
Strategic alliance contract
Slide 11:
---------
What We're Planning
Strategy
Increase shareholder value by:
1. Leveraging technology through:
Strategic alliances
Partnering
Licensing
Sale of assets
Slide 12:
---------
What We're Planning
Strategy - continued
Increase shareholder value by:
2. Conservative cash management
3. Utilizing world-class scientific advisors:
Pat Sluss, Ph.D.
Michael Hanson
Ken Faber, M.D.
Gary Gammerman, M.S., J.D.,
Pam Melon, Ph.D.
Slide 13:
---------
What We're Planning
Strategy - continued
Increase shareholder value by:
Concentrating on commercially attractive projects
Treatments for infertility
Alzheimer's disease
Type I diabetes
Parkinson's disease & ALS
Generation of `naturally derived' artificial organs
Spinal cord injury
(Markets Addressed: >> $5 Billion)
5
<PAGE>
Slide 14:
---------
Summary
Vitro is on a significantly different course
Vitro management and governance has been re-vitalized
Vitro's first drug product is through R&D
Vitro products are:
Unique
Address substantial markets
Slide 15:
---------
Summary
Vitro Shareholders should experience ever increasing value in their holdings
6
<PAGE>
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned hereunto duly authorized.
VITRO DIAGNOSTICS, INC.
Date: December 1, 2000 By: /s/ James R. Musick
-------------------------
James R. Musick, President and
Chief Executive Officer
7
